This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts

NUBEQA® (darolutamide)

Dosing

Packshot - Nubeqa

Dosing for NUBEQA® (darolutamide)

Two 300 mg tablets, twice daily with food and water
  • Total daily dose 1200 mg.
  • No dose adjustment is necessary for patients with mild or moderate renal impairment or mild hepatic impairment

For further information, please refer to the Summary of Product Characteristics (SmPC) link below:

NUBEQA®(darolutamide) SmPC
NUBEQA® (darolutamide) | Safety
Discover more about NUBEQA's safety profile.
PP-NUB-IE-0268-1, December 2025
NUBEQA® (darolutamide) | Morbidity
Explore NUBEQA® and its secondary endpoints.
PP-NUB-IE-0267-1, December 2025
NUBEQA® (darolutamide) | Overall Survival​
Explore NUBEQA and its impact on overall survival.
PP-NUB-IE-0266-1, December 2025

PP-NUB-IE-0269-1   |   December 2025

    Referencesexpand_less
    • 1
      NUBEQA® (darolutamide) Summary of Product Characteristics.